secwatch.observer — SEC 8-K summary
======================================

Issuer:     SCYNEXIS INC (SCYX)
CIK:        0001178253
Form:       8-K
Filed at:   2023-03-30T23:59:59+00:00
Accession:  0000950170-23-010748
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

SCYNEXIS licenses ibrexafungerp to GSK for $90M upfront plus up to $503M milestones
--------------------------------------------------------------------------------

- Upfront payment of $90M; eligible for up to $70M regulatory, $115M commercial, $242.5M sales, and $75.5M development milestones.
- GSK gets exclusive rights to ibrexafungerp (BREXAFEMME) outside Greater China; SCYNEXIS retains other assets with GSK ROFN.
- SCYNEXIS to repay ~$35.4M loan principal plus fees to Hercules/SVB upon receipt of upfront or by June 1, 2023.
- Transaction expected to close in Q2 2023, subject to HSR waiting period expiration.
- Royalties in mid-single to mid-teen percent on cumulative annual sales.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1178253/000095017023010748/0000950170-23-010748-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1178253/000095017023010748/scyx-20230330.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-010748

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer